ArticleBMJ open2026

Disitamab vedotin in combination with lenvatinib for patients with HER2-positive unresectable locally advanced or metastatic biliary tract cancer: study protocol of a phase II clinical trial.

Yongqiang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.